3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Neoplasm Metastasis
25
Leukemia, Myeloid, Acute
25
Breast Neoplasms
19
Prostatic Neoplasms
16
Myelodysplastic Syndromes
15
Lymphoma, Large B-Cell, Diffuse
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Multiple Myeloma
14
Lung Neoplasms
13
Colorectal Neoplasms
12
Carcinoma, Non-Small-Cell Lung
12
Triple Negative Breast Neoplasms
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Burkitt Lymphoma
11
Neoplasms
9
Lymphoma, Mantle-Cell
9
Leukemia, Myelomonocytic, Chronic
9
Ovarian Neoplasms
8
Melanoma
8
Lymphoma, T-Cell
8
Stomach Neoplasms
7
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Lymphoma, B-Cell
6
Myeloproliferative Disorders
5
Mouth Neoplasms
5
Lymphoma
5
Leukemia, Biphenotypic, Acute
5
Fallopian Tube Neoplasms
5
Interventions
Cisplatin
4
atezolizumab
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
abemaciclib
2
Vemurafenib
2
Radiosurgery
2
Pemetrexed
2
Mitomycin
2
Fulvestrant
2
Drug Therapy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
ribociclib
1
repotrectinib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
exemestane
1
enzalutamide
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Site
×
Biopsy
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled